Clinical Trial Update: Expanded Access for ATB200/AT2221 for the Treatment of IOPD

View source ↗

Summary

Expanded Access for ATB200/AT2221 to treat infantile-onset Pompe disease is available, per the sponsor Amicus Therapeutics.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pompe Disease Infantile-onset

Drugs mentioned

• ATB200/AT2221

Snippet

Sponsor: Amicus Therapeutics | Conditions: Pompe Disease Infantile-Onset | Status: AVAILABLE